期刊文献+

进食对健康受试者口服替米沙坦片剂药动学的影响 被引量:1

Influence of administering food on pharmacokinetics of telmisartan tablet in healthy subjects
原文传递
导出
摘要 目的研究在进食和空腹状态下中国健康受试者口服替米沙坦片的药动学差异。方法采用随机交叉给药方案,10名健康受试者进食或空腹单剂量口服替米沙坦片80mg,用高效液相色谱-荧光检测法测定血浆中替米沙坦的浓度,用DAS2.0软件计算其主要药动学参数。结果10名健康受试者在进食和空腹状态下单次口服替米沙坦片80mg的主要药动学参数ρmax分别为(455±s192)和(1186±1007)μg·L-1;tmax分别为(2.6±1.1)和(1.5±1.1)h;t1/2分别为(20±6)和(17±6)h;AUC0~t分别为(3503±1660)和(4895±2444)μg·h·L-1。进食状态下的ρmax和AUC0~t分别为空腹状态的(53±31)%和(73±20)%,tmax也明显延后。结论进食影响替米沙坦片的吸收速度和程度。 AIM To study the differences of pharmacokinetics of telmisartan tablet between administered with food and in fasted state in healthy Chinese volunteers. METHODS Ten healthy volunteers were given telmisartan tablet 80 mg administered with food or in fasted state by a random crossover study design, the concentration of telmisartan in human plasma was determined by HPLC with fluorescent detection (HPLC-FLD). The main pharmacokinetic parameters were calculated with DAS 2.0 software. RESULTS The main pharmacokinetic parameters of telmisartan when healthy volunteers administered with food or in fasted state were as follows: pmax were (455 ±s 192) and (1 186±1 007) μg·L^-1, tmax were (2.6±1.1) and (1.5 ±1.1) h, t1/2 were (20 ±6) and (17 ±6) h, AUC0-t were (3 503 ±1 660) and (4 895 ±2 444) μg·L^-1, respectively. pmax and AUCo, of telmisartan administered with food were (53 ± 31)% and (73 ±20)% of that in fasted state, respectively, and tmax was prolonged too. CONCLUSION Food affect the absorption rate and exposure of telmisartan.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2009年第6期439-441,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 替米沙坦 药动学 食品药物相互作用 色谱法 高压液相 光谱法 荧光 telmisartan pharmacokinetics food-drug interactions chromatography, high pressure liquid spectrometry, fluorescence
  • 相关文献

参考文献4

二级参考文献17

  • 1郑鹏程,李铜铃,许小红,张蓉琴,鄢琳,程强.替米沙坦3种制剂的人体生物等效性研究[J].中国新药与临床杂志,2005,24(7):536-539. 被引量:7
  • 2辛勤,刘善庭,葛顺,王传功,张欣,许宏凯.替米沙坦对脑缺血再灌注小鼠记忆障碍的改善作用[J].中国新药与临床杂志,2006,25(9):696-699. 被引量:4
  • 3Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-A revisit with a decade of progress [ J ]. Pharm Res, 2000,17(12) :1551-1557. 被引量:1
  • 4Noriko D, Richard ZL, Fakhreddin J. High-performance liquid chromatographic analysis of angiotensin Ⅱ receptor antagonist valsartan using a liquid extraction method [ J ]. Journal of Chromatography,2002.766 (6) :345-349. 被引量:1
  • 5Meclellan KJ, Markham A. Telmisartan. Drugs, 1998, 56(6) : 1039. 被引量:1
  • 6Smith DH. Treatment of hypertension with an angiotensin Ⅱ - receptor antagonist compared with an angiotensin - converting enzyme inhibitor: a review of clinical studies of telmisarsin and enalapril. Clin Ther, 2002, 24(10) : 1484. 被引量:1
  • 7Stangier J,Su CA, Schondorfer G,et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20mg and 120mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol, 2000, 40(12 pt 1) : 1355. 被引量:1
  • 8Stangier J, Su CA, Hendriks MG,et al. The effect of telmisartan on the steady - state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol, 2000, 40(12 pt 1) : 1373. 被引量:1
  • 9Stangier J, Schmid J, Turck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [ ^14C ] telmisartan in healthy volunteers. J Clin Pharmacol, 2000, 40( 12 pt 1 ) : 1312. 被引量:1
  • 10Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res, 2000, 28(4) : 149. 被引量:1

共引文献11

同被引文献23

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部